Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia

Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022
bởiRoshini Claire Anthony
Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.
Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022
Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
bởiTristan Manalac
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.